ACCEL Lite: What About Aspirin From The Time of Primary PCI?
The PREMIUM trial evaluates whether aspirin can be safely omitted in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI), with the goal of simplifying antiplatelet therapy and reducing bleeding risk. The trial found that a strategy of avoiding aspirin was associated with favorable clinical outcomes compared with standard aspirin-based therapy. If confirmed in broader practice, these findings could challenge the long-standing routine use of aspirin from the time of primary PCI.
In this episode, W. Douglas Weaver MD, MACC and Gaku Nakazawa, MD, PhD, FACC discuss PREMIUM: Aspirin Omission at the Time of Primary PCI in STEMI.
Related References:
- Miyashita K, Muramatsu T, Revaiah PC, et al. Aspirin-Free Prasugrel Monotherapy After Percutaneous Coronary Intervention in Patients With Non-ST Elevation Acute Coronary Syndrome. Circ J. 2026;90(3):354-363. doi:10.1253/circj.CJ-25-0356
- Guimarães PO, Franken M, Tavares CAM, et al. Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes. N Engl J Med. 2025;393(21):2095-2106. doi:10.1056/NEJMoa2507980 Natsuaki M, et al. An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial. Circulation. 2024;149:585-600.
Clinical Topics: Invasive Cardiovascular Angiography and Intervention
Keywords: ACCELLite, ESC26, Aspirin, Percutaneous Coronary Intervention